Test and Start for People Living With HIV and Who Use Drugs in Low and Middle Income Countries
DOI:
https://doi.org/10.17140/HARTOJ-3-121Keywords:
ART for all, Drug use, Substance use disorder treatment, HIV infection, Alcohol use, Test and StartAbstract
“Test and Start” implements the World Health Organization (WHO) recommendation of “treat all” by providing anti-retroviral treatment to persons newly diagnosed with HIV infection, at the time of their diagnosis. This HIV treatment algorithm is derived from recent international clinical trials and the recent international HIV treatment guidelines by WHO, recommending all people living with HIV be provided anti-retroviral treatment. This “treat all” recommendation removes any and all limitations for receiving anti-retroviral treatment for all people living with HIV, including people who use drugs. However, there are a limited number of “Test and Start” programs that have focused on the barriers to anti-retroviral treatment for people who use drugs. With an increasing number of low and middle income countries developing guidance for “Test and Start” programs, this articles identified four elements that support access to and successful initiation of the early initiation of anti-retroviral treatment for people living with HIV, who use drugs. The elemental services are: outreach with social services, screening for and management of substance use disorders, comprehensive primary care and differentiated care in anti-retroviral treatment. Together these services can provide a supportive foundation for “Test and Start” programs for people living with HIV, who use drugs.
References
World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Prevention HIV Infection. Recommendations for a public Health Approach. 2nd ed. Geneva, Switzerland: WHO Document Production Services; 2013.
Boyer S, Iwuji C, Gosset A, et al. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: Early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care. 2016; 28 Suppl 3: 39-51. doi: 10.1080/09540121.2016.1164808 Activities that “Support Test and Start” -
Plazy M, Dabis F, Naidu K, Orne-Gliemann J, Barnighausen T, Dray-Spira R. Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infect Dis. 2015; 15: 452. doi: 10.1186/s12879-015-1207-2
Federal Ministry of Health, Nigeria. National guidelines for hiv and aids treatment and care in adolescents and adults. 2010. Web site. http://www.who.int/hiv/pub/guidelines/nigeria_art. pdf. Accessed August 29, 2016
Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010; (3): CD008272. doi: 10.1002/14651858.CD008272.pub2
Ministry of Health, Government of Botswana. 2012 Botswana National HIV & AIDS treatment Guidelines. Web Site. http:// www.emtct-iatt.org/wp-content/uploads/2013/04/Botswana_ National-HIV-AIDS-Guidelines_2012.pdf. Accessed August 29, 2016
World Health Organization. WHO issues new HIV recommendations calling for earlier treatment. Web Site. http:// www.who.int/mediacentre/news/releases/2013/new_hiv_ recommendations_20130630/en/. Accessed August 29, 2016
Myron S, Cohen MD, Ying Q, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365: 493-505. doi: 10.1056/NEJMoa1105243
Danel C, Moh R, Gabillard D, et al.Atrial of early antiretroviral and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373(9): 808-822. doi: 10.1056/NEJMoa1507198
INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373(9): 795-807. doi: 10.1056/NEJMoa1506816
United States AID. Test and Start: Optimizing Antiretroviral Therapy Services to Save Lives. Web site. https://www.usaid. gov/what-we-do/global-health/hiv-and-aids/technical-areas/ test-and-start. Accessed August 29, 2016
UNAIDS. Geneva: UNAIDS; 2014. The gap report. Web site. http://www.unaids.org/en/resources/campaigns/2014/2014 gapreport/gapreport. Accessed August 29, 2016
International Advisory Panel on HIV Care Continuum Optimization. IAPAC guidelines for optimizing the hiv care continuum for adults and adolescents. Int Assoc Provid AIDS Care.2015; 14 Suppl 1: S3-S34. doi:10.1177/2325957415613442
Vu NT, Maher L, Zablotska I. Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis. J Int AIDS Soc. 2015; 18(1): 19273. doi: 10.7448/IAS.18.1.19273
Vagenas P, Azbel L, Polonsky M, et al. A review of medical and substance use co-morbidities in central asian prisons: implications for hiv prevention and treatment. Drug Alcohol Depend. 2013; 132 Suppl 1: S25-S31. doi: 10.1016/j. drugalcdep.2013.07.010
Degenhardt L, Whiteford HA, Ferrari AJ et al. Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382: 1564-1574. doi: 10.1016/S0140-6736(13)61530-5
Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The impact of alcohol use and related disorders on the hiv continuum of care: a systematic review: alcohol and the hiv continuum of care. Curr HIV/AIDS Rep. 2015; 12(4): 421-436. doi: 10.1007/s11904-015-0285-5
Meade CS, Towe SL, Watt MH, et al. Addiction and treatment experiences among active methamphetamine users recruited from a township community in Cape Town, South Africa: A mixed-methods study. Drug Alcohol Depend. 2015; 152: 79-86. doi: 10.1016/j.drugalcdep.2015.04.016
Zhang XD, Kelly-Hanku A, Chai JJ, Luo J, Temmerman M, Luchters S. Sexual and reproductive health risks amongst female adolescents who use amphetamine-type stimulants and sell sex: a qualitative inquiry in Yunnan, China. Harm Reduct J. 2015; 12: 34. doi: 10.1186/s12954-015-0065-y
Beyrer C, Razak MH, Jittiwutikarn J, et al. Methamphetamine users in northern Thailand: changing demographics and risks for HIV and STD among treatment-seeking substance abusers. Int J STD AIDS. 2004; 15(10): 697-704. doi: 10.1177/095646240401501012
Kresina TF, Condor LD, Lapidos-Salaiz IF. The impact of screening, diagnosis and management of substance use and addictive disorders in hiv care in low and middle income countries. Res HIV Retroviral Infect. 2016; 1: 1-10. Web site. http://crescopublications.org/pdf/RHRIOA/RHRIOA-1-003. pdf. August 29, 2016
Kresina TF, Conder LD, Lapidos-Salaiz IF. the impact of screening, diagnosis and management of alcohol use disorders in hiv care in low and middle income countries. Ann Pub Health Res 2016; 3(1): 1035. Web site. https://www.jscimedcentral. com/PublicHealth/publichealth-3-1035.pdf. Accessed 29, 2016
World Health Organization. Pharmacological treatment of mental disorders in primary health care. 2009. Web Site. http:// apps.who.int/iris/bitstream/10665/44095/1/9789241547697_ eng.pdf. Accessed August 29, 2016
World Health Organization. Consolidated Guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva, Switzerland; WHO Press; 2014. Web Site. http://www. who.int/hiv/pub/guidelines/keypopulations/en/. Access August 29, 2016
World Health Organization. Basic Principles for Treatment and Psychosocial Support of Drug Dependent People Living with HIV/AIDS 2006. Web site. http://www.who.int/substance_abuse/ publications/basic_principles_drug_hiv.pdf. Accessed August 29, 2016
World Health Organization. Management of Substance Abuse. Web site. http://www.who.int/substance_abuse/ publications/treatment/en/. Accessed August 29, 2016.
Fornili KS. Part 2: Screening, brief intervention and referral to treatment plus recovery management: a proposed model for recovery-oriented primary care. J Addict Nurs. 2016; 27(2): 86- 93. doi: 10.1097/JAN.0000000000000119
Vujanovic AA, Meyer TD, Heads AM, Stotts AL, Villarreal YR, Schmitz JM. Cognitive-behavioral therapies for depression and substance use disorders: an overview of traditional, third-wave, and transdiagnostic approaches. Am J Drug Alcohol Abuse. 2016; 5: 1-14. doi: 10.1080/00952990.2016.1199697
Davis DR, Kurti AN, Skelly JM, Redner R, White TJ, Higgins ST. A review of the literature on contingency management in the treatment of substance use disorders, 2009-2014. Prev Med. 2016; pii: S0091-7435(16)30214-6. doi: 10.1016/j. ypmed.2016.08.008
Drapkin ML, Wilbourne P, Manuel JK, Baer J, Karlin B, Raffa S. National dissemination of motivation enhancement therapy in the veterans health administration: training program design and initial outcomes. J Subst Abuse Treat. 2016; 65: 83- 87. doi: 10.1016/j.jsat.2016.02.002
Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015; 23(2): 63-75. doi: 10.1097/ HRP.0000000000000075
Lee J, Kresina TF, Campopiano M, Lubran R, Clark HW. Use of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary care. Biomed Res Int. 2015; 2015: 137020. doi: 10.1155/2015/137020
Batkis MF, Treisman GJ, Angelino AF. Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies. AIDS Patient Care STDS. 2010; 24(1): 15-22. doi: 10.1089/apc.2009.0242
World Health Organization. mhGAP Mental Health Gap Action Programme. Scaling up care for mental, neurological and substance use disorders. 2008. Web site. http://www.who. int/mental_health/evidence/mhGAP/en/index.html. Accessed August 29, 2016.
Kresina TF, Lubran R. Improving public health through the implementation of medication assisted treatment. Int J Environ Res Public Health. 2011; 8: 4102-4117.
Kresina TF, Lubran R, Clark HW, Cheever LW. Mediation assisted treatment, HIV/AIDS and the continuum of response for people who inject drugs. Adv Prev Med. 2012; 2012: 541489. Web site. http://www.hindawi.com/journals/apm/2012/541489/. Accessed August 29, 2016.
Hayashi K, Ti L, Avihingsanon A, et al. Compulsory drug detention exposure is associated with not receiving antiretroviral treatment among people who inject drugs in Bangkok, Thailand: a cross-sectional study. Subst Abuse Treat Prev Policy. 2015; 10: 16. doi: 10.1186/s13011-015-0013-6
Des Jarlais DC, Thi Huong D, Thi Hai Oanh K, et al. Prospects for ending the HIV epidemic among persons who inject drugs in Haiphong, Vietnam. Int J Drug Policy. 2016; 32: 50-56. doi: 10.1016/j.drugpo.2016.02.021
Tran DA, Shakeshaft A, Ngo AD, et al. Determinants of antiretroviral therapy initiation and treatment outcomes for people living with HIV in Vietnam. HIV Clin Trials. 2013; 14(1): 21-33. doi: 10.1410/hct1401-21
Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One. 2013; 8(3): e59643. doi: 10.1371/ journal.pone.0059643
Bruce RD, Kresina TF, McCance-Katz E. Medication assisted treatment and HIV/AIDS: Issues in the diagnosis, care and treatment of HIV-infected drug users. AIDS. 2010; 24(3): 331-340. doi: 10.1097/QAD.0b013e32833407d3
Low AJ, Mburu G, Welton NJ, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis. 2016; pii: ciw416. doi: 10.1093/cid/ciw416
Nosyk B, Min JE, Evans E, et al. The effects of opioid substitution treatment and highly active antiretroviral therapy on the cause-specific risk of mortality among hiv-positive people who inject drugs. Clin Infect Dis. 2015; 61(7): 1157-1165. doi: 10.1093/cid/civ476
Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: Results from a multisite study. J Acquir Immune Defic Syndr. 2011; 56 (Suppl 1): S22-S32. doi: 10.1097/ QAI.0b013e318209751e
Haig T. Randomized controlled trial proves effectiveness of methadone maintenance treatment in prison. Can HIV/AIDS Policy Law Rev. 2003; 8(3): 48-53. Web site. http://europepmc. org/abstract/med/15108656. Accessed August 29, 2016
Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health. 2010; 87(4): 592-602. doi: 10.1007/s11524-010-9438-4
Global HIV Policy Watch. 2016. Web site: www. HIVPolicyWatch.org. Accessed August 24, 2016
Lugongo B. ARVs now for any CD4 count. Tanzania Daily News 24 August 2016. Web site. http://dailynews.co.tz/index. php/home-news/52970-hiv-aids-patients-for-arvs-therapy-at-any-cd4-count. Accessed August 29, 2016
El-Bassel N, Shaw SA, Dasgupta A, Strathdee SA. Drug use as a driver of HIV risks: re-emerging and emerging issues. Curr Opin HIV AIDS. 2014; 9(2): 150-155. doi: 10.1097/ COH.0000000000000035
Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365: 493-505. doi: 10.1056/NEJMoa1105243
TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. Supplementary Appendix. N Engl J Med. 2015; 373: 808-822. doi: 10.1056/NEJMoa1507198
The INSIGHTSTARTStudy Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373(9): 795-807. doi: 10.1056/NEJMoa1506816
Batista P, Deren S, Banfield A, et al. Challenges in recruiting people who use drugs for hiv-related biomedical research: perspectives from the field. AIDS Patient Care STDS. 2016; 30(8): 379-384. doi: 10.1089/apc.2016.0135
PEPFAR Scientific Advisory Board. Recommendations Regarding Provision of ART for all Persons Living with HIV (“Test and START”). 2015.
Mbonye M, Seeley J, Nalugya R,et al. Test and treat: the early experiences in a clinic serving women at high risk of HIV infection in Kampala. AIDS Care. 2016; 28 Suppl 3: 33-38. doi: 10.1080/09540121.2016.1164804
Zolfo M, De Weggheleire A, Schouten E, Lynen L. Time for “test and treat” in prevention of mother-to-child transmission programs in low- and middle-income countries. J Acquir Immune Defic Syndr. 2010; 55(3): 287-289. doi: 10.1097/ QAI.0b013e3181eef3da
Weiss HA, Vandepitte J, Bukenya JN, et al. High levels of persistent problem drinking in women at high risk for hiv in kampala, uganda: a prospective cohort study. Int J Environ Res Public Health. 2016; 13(2): 153-157. doi: 10.3390/ ijerph13020153
Schwarcz S, Hsu LC, Scheer S. Disparities and trends in viral suppression during a transition to a “Test and Treat” approach to the hiv epidemic, san francisco, 2008-2012. J Acquir Immune Defic Syndr. 2015; 70(5): 529-537. doi: 10.1097/ QAI.0000000000000794
Saleem HT, Mushi D, Hassan S,et al. “Can’t you initiate me here?”: Challenges to timely initiation on antiretroviral therapy among methadone clients in Dar es Salaam, Tanzania. Int J Drug Policy. 2016; 30: 59-65. doi: 10.1016/j.drugpo.2015.12.009
Low AJ, Mburu G, Welton NJ et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: A systematic review and meta-analysis. Clin Infect Dis. 2016; pii: ciw416. doi: 10.1093/cid/ciw416
Dutta A, Wirtz AL, Baral S, Beyrer C, Cleghorn FR. Key harm reduction interventions and their impact on the reduction of risky behavior and HIV incidence among people who inject drugs in low-income and middle-income countries. Curr Opin HIV AIDS. 2012; 7(4): 362-368. doi: 10.1097/COH.0b013e328354a0b5
Klein A, Saphonn V, Reid S. Reaching out and reaching up-developing a low cost drug treatment system in Cambodia. Harm Reduct J. 2012; 9: 11. doi: 10.1186/1477-7517-9-11
World Health Organization, Europe. Good practices in Europe: HIV prevention for People Who Inject Drugs implemented by the International HIV/AIDS Alliance in Ukraine. 2014. Web site. http://www.euro.who.int/__data/assets/pdf_file/0003/254352/ FINAL-Ukraine-Good-Practice-July-2014-with-covers.pdf. Accessed August 29, 2016
Risher K, Mayer KH, Beyrer C. HIV treatment cascade in MSM, people who inject drugs, and sex workers. Curr Opin HIV AIDS. 2015; 10(6): 420-429. doi: 10.1097/ COH.0000000000000200
Myers BJ. Primary health care for people who inject drugs in low and middle income countries. Int J Drug Policy. 2012; 23(2): 105-106. doi: 10.1016/j.drugpo.2011.09.014
Holmes CB, Sanne I. Changing models of care to improve progression through the HIV treatment cascade in different populations. Curr Opin HIV AIDS. 2015; 10(6): 447-450. doi: 10.1097/COH.0000000000000194
Wouters E, Van Damme W, van Rensburg D, Masquillier C, Meulemans H. Impact of community-based support services on antiretroviral treatment programme delivery and outcomes in resource-limited countries: a synthetic review. BMC Health Serv Res. 2012; 12: 194. doi: 10.1186/1472-6963-12-194
Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, et al. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015; 528(7580): S68-S76. doi: 10.1038/nature16046
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
